In continuation to intimation dated March 27, 2024 and pursuant to Regulations 30, 33, 42 and 43 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, Novartis India has informed that the Board of Directors of the Company at its Meeting held today i.e. May 10, 2024 have approved the following matters: The Board has approved the Audited Financial Statement for the year ended March 31, 2024 and Audited Financial Results for the quarter & year ended March 31, 2024, as recommended by the Audit Committee. The Board has recommended final dividend of Rs 25 per equity share (of the face value of Rs 5 each) for the financial year ended March 31, 2024, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting. Accordingly, the said final dividend, if approved by the shareholders, will be paid on or after August 5, 2024. The 76th AGM of the Company will be held on Wednesday, July 31, 2024 at 11:00 AM (IST) through Video Conferencing / Other Audio-Visual Means in compliance with the applicable provisions of the Circulars issued in this regard by Ministry of Corporate Affairs and Securities and Exchange Board of India from time to time. The Register of Members and Share Transfer books shall be closed from Wednesday, July 24, 2024 to Wednesday, July 31, 2024, for determining the eligibility of shareholders for payment of dividend, if approved by the shareholders at the AGM; etc.
The above information is a part of company’s filings submitted to BSE.